Friday 6 November 2026 Export PCVX’s income statement to Excel — free account

Vaxcyte, Inc.

PCVX Healthcare Biotechnology

EPS: −61.5%
Free cash flow: −92.6%

Quarter to June 2026, against a year earlier

63.82 1.90 +3.07%

Follow PCVX

Alert me

Market cap: $9.8B
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Valuation Filings

Vaxcyte, Inc. 8-K filed May 8, 2024

Period ended May 8, 2024 · Filed May 8, 2024 · accepted 4:08 PM ET · Document on sec.gov · Filing index

2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov The press release